Jim Scopa
Director, Chair of Audit Committee at Neuron23 Inc.
San Francisco, California
Overview
Work Experience
Director, Chair of Audit Committee
2021 - Current
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Raised $213,500,000.00 from Surveyor Capital, Cowen Healthcare Investments, Acorn Bioventures, Westlake Village BioPartners, SoftBank Vision Fund, Perceptive Advisors, Redmile Group, HBM Partners, Kleiner Perkins and HBM Healthcare Investments.
Director, Chair of Compensation Committee, Member of Audit Committee
2019
Member of Compensation and Audit Committees
Adverum Biotechnologies is a gene therapy company that focuses on developing medicines that can offer therapeutic benefits to patients.
Raised $814,872,635.00 from 5AM Ventures, Vivo Capital, Venrock Healthcare Capital Partners, Commodore Capital, Logos Capital, TCG Crossover, Frazier Life Sciences and Samsara BioCapital.
Member of Investment Advisory Committee, Member of Advisory Board
2017
Advisor to Australian based venture capital firm with $330 million under management
Director, Chair of Audit Committee and Member of Compensation Committee
2015 - 2023
Member of Compensation Committee, Chair of Audit Committee
Director, Member of Audit Committee, Chair of Compensation Committee
2020 - 2023
Sold to Eli Lilly in August 2023 for $2.4 billion
Fellow, Distinguished Careers Institute ("DCI")
2017 - 2018
Focus on translational and regenerative medicine.
Managing Director -- Member of Investment Committee
2005 - 2017
Previously served on the boards of Semma Therapeutics sold to Vertex for $950 million, True North Therapeutics, sold to Bioverativ for $825 million in cash and future milestones, June 2017; Solasia K.K., IPO on Tokyo Stock Exchange March 2017 and fully exited June 2017; Nevro Corp. ("NVRO") Nasdaq IPO November 2014 and fully exited in August 2016; iPierian, Inc. sold to Bristol Myers Squibb for cash and milestones of $725 million in April 2014 ;TriVascular, Inc. Nasdaq IPO in April 2014 and sold to Endologix for $120 million in February 2016; Peplin, Inc.("PEP":ASX) sold to LEO Pharmaceuticals for $300 million in November 2009. Extensive experience on Compensation and Audit Committees for both public and private companies.
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
Partner and Managing Director
2002 - 2005
Co-Head Health Care Investment Banking; Member of Investment Committee of Thomas Weisel Health Care Venture Fund
Managing Director
1990 - 2002
Global Co-Head Health Care Investment Banking (1999-2002);Managing Director, Health Care Banking (1996-1999);Focus in Life Sciences and Medical Devices
Associate Investment Banking
1986 - 1989
Technology and Life Sciences Group
Education
MBA
1982 - 1986
J.D.
1982 - 1986
A.B. History and Science (Biology)
1976 - 1980